-
Young Jin Choi,
Yoon La Choi,
Eun Yoon Cho,
Young Kee Shin,
Ki Woong Sung,
Yu Kyeong Hwang,
Sang Jin Lee,
Gu Kong,
Jeong Eon Lee,
Jee Soo Kim,
Jung Han Kim,
Jung-Hyun Yang,
Seok Jin Nam
[show abstract]
[hide abstract]
ABSTRACT: Purpose Abnormal expression of the cell cycle regulatory protein Bmi-1 has been studied in breast cancer, but the clinical relevance
has not been fully elucidated. We studied the expression of Bmi-1 protein in breast cancer patients to define its clinical
significance in breast cancer. Experimental Design Tissue microarrays were performed to evaluate the expression of Bmi-1 by immunohistochemistry in tumor tissues from 960 patients
with stage I–III breast cancer. We assessed the relationship between the expression of Bmi-1 and pathologic prognostic indices
as well as clinical long-term follow up outcome. Results Bmi-1 was expressed in 53.2% of breast cancer patients by immunohistochemistry, and the expression of Bmi-1 was significantly
correlated with favorable prognostic indices at diagnosis. In univariate analysis, patients with Bmi-1 expression showed favorable
relapse-free survival (88.6±2.7% vs. 72.3±4.3%, P=0.041) and favorable overall survival (93.5±2.2% vs. 82.6±3.5%, P<0.001) than patients without Bmi-1 expression. According to multivariate analyses, Bmi-1 expression was identified as independent
prognostic factor for overall survival with a statistical significance (hazard ratio of Bmi-1 (−) patients compared to Bmi-1
(+) patients, 1.744; 95% CI, 1.013–3.003; P=0.045). This correlation of Bmi-1 expression with favorable overall survival was maintained in patients underwent uniform
chemotherapy, regardless of undergoing adjuvant chemotherapy. In a subset analysis according to ER status, Bmi-1 expression
associated with favorable overall survival only in ER-positive patients. Conclusions Bmi-1 expression assessed with Immunohistochemistry may be associated with favorable overall survival in breast cancer patients,
especially in patients with ER-positive breast cancer.
Breast Cancer Research and Treatment 04/2012; 113(1):83-93. · 4.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Endoscopic thyroidectomy is gaining greater acceptance because of its excellent cosmetic result. As the surgical skill and understanding of the endoscopic cervical anatomy has improved, the surgical indications for endoscopic thyroidectomy have recently expanded to small size thyroid cancer. Despite the many advantages of laparoscopic surgery, there have been incidental reports about recurrences at the site of insertion of the laparoscope or other instruments in other cancers. Herein, we present a case of 25-year-old woman who had recurrent cancers around the operative bed and subcutaneous tunnel after endoscopic thyroidectomy.
Surgical laparoscopy, endoscopy & percutaneous techniques 05/2008; 18(2):197-201. · 1.23 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Despite the sensitivity and accuracy of sentinel lymph node biopsy (SLNB), the number of false negative (FN) results is still relatively high, which has prompted much investigation. We studied the effectiveness of the biopsy of suspicious palpable lymph nodes (LNs) in reducing the number of FN results.
We reviewed the medical records of 865 breast cancer patients who underwent successful SLNB at a single institution. After excising the blue-stained or radioactive nodes, all suspicious palpable LNs that were not either blue-stained or radioactive were also excised.
Sampling of a suspicious palpable LN was done in 342 (39.5%) of the 865 patients. The average number of suspicious palpable nodes was 1.9. The suspicious nodes harbored metastasis in 19 of the 342 patients. Both blue-stained and radioactive metastatic SLNs were found in 8 patients, whereas the palpable nodes were the only ones involved in the other 11. LN involvement was identified solely by biopsy of a suspicious palpable LN in 11 (6.5%) of 170 patients with SLN metastasis (6.5%).
Biopsy of a suspicious palpable LN should be done as part of SLNB to reduce the number of FN results of SLNs in breast cancer patients.
Surgery Today 02/2008; 38(5):390-4. · 1.22 Impact Factor
-
Jaewon Choi,
Yu Kyeong Hwang, Young Jin Choi,
Ki Eun Yoo,
Jeong Han Kim,
Seok Jin Nam,
Jung Hyun Yang,
Sang Jin Lee,
Keon Hee Yoo,
Ki Woong Sung,
Hong Hoe Koo,
Young Hyuck Im
[show abstract]
[hide abstract]
ABSTRACT: Neuronal apoptosis inhibitory protein (NAIP) is a recently identified inhibitor of apoptosis protein. However, the clinical relevance of NAIP expression is not completely understood. In an attempt to determine the clinical relevance of NAIP expression in breast cancer, the levels of NAIP and survivin expression were measured in 117 breast cancer samples and 10 normal breast tissues using quantitative reversetranscriptase-polymerase chain reaction. While there was no evidence of NAIP expression in the normal breast tissue, NAIP was expressed in all breast cancer samples. The level of NAIP expression in breast cancer was significantly higher (257 times) than in the universal tumor control. There was a strong correlation between the level of NAIP expression and the level of survivin expression (p=0.001). The level of NAIP expression in patients with a large tumor (>/=T2) and patients with an unfavorable histology (nuclear grade III) was significantly higher than in those patients with a small tumor (T1) and patients with a favorable histology (nuclear grade I, II) (p=0.026 and p=0.050, respectively). Although the level of NAIP expression was higher in patients with other unfavorable prognostic factors, it was not significant. The three-year relapse-free survival rate was not significantly the patients showing high NAIP expression and patients showing low NAIP expression (86.47plusmn;4.79% vs. 78.74plusmn;6.57%). Further studies should include the expressions of NAIP in a larger number of patients and for a longer period of follow-up to evaluate correlation with metastasis and treatment outcome. In conclusion, NAIP is overexpressed in breast cancer patients with unfavorable clinical features such as stage and tumor size, suggesting that NAIP would play a role in the disease manifestation.
Journal of Korean Medical Science 09/2007; 22 Suppl:S17-23. · 0.99 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The ultrarapid immunohistochemistry (IHC) technique was applied to the intraoperative examination of sentinel lymph nodes (SLNs) because routine SLN frozen section examinations sometimes produce false-negative results. The present study was undertaken to develop a reliable protocol for the ultrarapid IHC of SLNs.
SLNs from 79 breast cancer patients with clinically negative axillary node were examined intraoperatively by frozen hematoxylin-eosin (H&E) stain and by ultrarapid cytokeratin IHC assay. On the basis of the result of serially sectioned permanent study, the sensitivity and accuracy of each intraoperative technique were compared.
The total number of dissected SLNs was 178 with a mean of 2.3 (1-5) per patient. The mean turnaround time for ultrarapid IHC was 20 min. The sensitivity rates of frozen H&E staining and ultrarapid IHC were 70.0 and 85.0%, respectively (P = 0.083). Each method had a specificity of 100%. The accuracy rates for frozen H&E staining and rapid IHC were 92.4 and 96.2%, respectively (P = 0.083). Ultrarapid IHC detected one additional patient with sentinel node micrometastasis and two additional patients with isolated tumor cells (ITCs). In those patients, two underwent completion axillary dissection simultaneously and could avoid a second operation.
Ultrarapid cytokeratin IHC enhanced the intraoperative detection of sentinel node micrometastasis and ITCs in breast cancer without consuming much time. In patients who need completion axillary dissection after sentinel node biopsy, this technique could be helpful in avoiding a second operation.
Japanese Journal of Clinical Oncology 09/2006; 36(8):489-93. · 1.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Metastatic breast cancer is still defined as an incurable disease, with the lungs being the most common metastatic sites in breast cancer patients. Epidermal growth factor receptor (EGFR), a member of receptor tyrosine kinase family, is known to be involved in survival, migration, angiogenesis and metastasis of cancer. The spontaneous pulmonary metastasis mouse model was applied to evaluate the effects of the EGFR tyrosine kinase inhibitor, erlotinib, on the prevention of pulmonary metastasis in curatively resected breast carcinoma. The expression of EGF and EGFR was significantly strong in pulmonary metastatic nodules compared to those in primary breast carcinoma tissue. A treatment of erlotinib (oral gavage, 50 mg/kg/day, every day for 6 weeks) given to mastectomized mice inhibited the incidence of pulmonary metastasis. The number of metastatic pulmonary nodules was significantly reduced in the erlotinib-treated group compared with the control. Therefore, erlotinib may play a role in preventing pulmonary metastasis, which shows the strong expression of EGF and EGFR after curative resection of primary breast cancer.
Oncology Reports 08/2006; 16(1):119-22. · 1.84 Impact Factor
